On this page
- TL;DR
- BPH VA rating criteria (DC 7527)
- Is BPH presumptive for Agent Orange or the PACT Act?
- BPH and urinary problems after prostate cancer treatment
- BPH that started before service: the aggravation question
- How to prove BPH is service connected
- Why VA denies BPH claims
- Questions veterans ask about BPH
- Bottom Line
Non-cancer prostate conditions are a large share of the Board's prostate caseload. Across 5,302 decided Board rulings on prostate conditions other than cancer from 2021 to 2026, 22.7% were granted, 32.8% denied and 44.5% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. Prostate cancer has more decided rulings and a higher grant rate, and its rating math, presumptions and diagnostic codes differ in ways that matter for claim strategy. If your claim is for cancer, see the prostate cancer guide.
The non-cancer prostate conditions veterans claim include benign prostatic hypertrophy (BPH, an enlarged prostate), chronic prostatitis, and prostatic dysfunction. BPH and prostatic dysfunction rate under DC 7527 ("Prostate gland injuries, infections, hypertrophy, postoperative residuals, bladder outlet obstruction") in the genitourinary chapter at 38 CFR § 4.115b. Chronic prostatitis is listed under DC 7525, which says to rate it as urinary tract infection. Neither code has an independent rating ladder. DC 7527 tells the rater to look at the genitourinary symptoms the prostate condition is producing and rate under whichever symptom category is predominant: voiding dysfunction (urine leakage, urinary frequency, or obstructed voiding) or urinary tract infection.
BPH is noncancerous growth of the prostate tissue around the urethra. As it squeezes the urethra, it can cause urinary symptoms, urinary retention, or infections from incomplete bladder emptying. It becomes more common with age: autopsy studies find it in 50 to 60 percent of men in their 60s and 80 to 90 percent of men over 70.
That structural feature shapes how most non-cancer prostate claims actually get decided. The diagnosis is the easy part. The fight is over which symptom code applies and what tier it supports.
TL;DR
- 5,749 Board rulings on prostate conditions other than cancer from 2021 to 2026, 5,302 of them decided. Outcomes: 22.7% granted, 32.8% denied, 44.5% remanded. Remand is the most common outcome, and the grant rate is 2.0 points below the Board-wide grant rate of 24.7 percent.
- DC 7527 rates non-cancer prostate conditions through the criteria in 38 CFR § 4.115a, which sets the genitourinary dysfunction criteria. Voiding dysfunction (urine leakage, urinary frequency, or obstructed voiding) and urinary tract infection are the rating bases. Chronic prostatitis is listed under DC 7525 and rated as urinary tract infection.
- Waking at night to urinate counts: two times a night meets the 10 percent urinary frequency level.
- In the Board's 2021 to 2026 service connection rulings on these conditions, claims argued under a presumption and claims argued as direct service connection were granted at similar rates, and secondary claims were granted least often. The Board section below shows all three.
- The Agent Orange and PACT Act presumptions don't list BPH or chronic prostatitis directly, but the herbicide framework covers prostate cancer, and the line between cancer and severe non-cancer prostate conditions can be procedurally significant.
- Camp Lejeune contaminated water has a presumptive list, 38 CFR § 3.309(f), that includes bladder cancer and kidney cancer but not BPH or chronic prostatitis.
- Appeals for a higher rating were granted at about the same rate as these conditions overall. Without urine leakage, the frequency and obstruction criteria top out at 40 and 30 percent; the 40 and 60 percent leakage levels need absorbent pads changed at least twice a day.
- Among rulings the Board granted or denied, those with a private medical opinion in the record were granted more often than these conditions overall, an association rather than a cause. The Board section below shows what the Board did with medical opinions.
BPH VA rating criteria (DC 7527)
DC 7527 is unusual in the rating schedule because it doesn't tell the rater what percentage to assign. It tells the rater where to look.
The regulatory text is short.
"Prostate gland injuries, infections, hypertrophy, postoperative residuals, bladder outlet obstruction: Rate as voiding dysfunction or urinary tract infection, whichever is predominant."
That's the whole code. Its only instruction is to rate through the predominant symptom area. The actual rating depends on which symptom dominates the clinical picture.
The genitourinary dysfunction criteria at 38 CFR § 4.115a rate voiding dysfunction as urine leakage, urinary frequency, or obstructed voiding, and rate urinary tract infection separately. When a code points to these areas, § 4.115a says only the predominant area of dysfunction is rated.
Urine leakage (voiding dysfunction)
This is the urine leakage category, for veterans with documented urinary leakage, incontinence, or the need for absorbent materials. The ladder runs as follows.
- 20%: Requiring the wearing of absorbent materials which must be changed less than 2 times per day
- 40%: Requiring the wearing of absorbent materials which must be changed 2 to 4 times per day
- 60%: Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than 4 times per day
Leakage is a recognized complication of prostate surgery, especially radical prostatectomy for cancer, and it is the rating basis when you need absorbent pads or an appliance.
Urinary frequency and waking at night to urinate
This is the rating category for veterans with documented urinary frequency without significant incontinence. The ladder runs as follows.
- 10%: Daytime voiding interval between 2 and 3 hours, or; awakening to void 2 times per night
- 20%: Daytime voiding interval between 1 and 2 hours, or; awakening to void 3 to 4 times per night
- 40%: Daytime voiding interval less than 1 hour, or; awakening to void 5 or more times per night
Nighttime voiding counts on its own. Waking to urinate twice a night meets the 10 percent level even if daytime intervals are longer, so a count of nighttime awakenings belongs in the record.
Obstructed voiding
This is the rating category for veterans with documented urinary retention or obstructive symptoms, a common BPH pattern. The ladder runs as follows.
- 0%: Obstructive symptomatology with or without stricture disease requiring dilatation 1 to 2 times per year
- 10%: Marked obstructive symptomatology (hesitancy, slow or weak stream, decreased force of stream) with any one or combination of: post void residuals greater than 150 cc; markedly diminished peak flow rate on uroflowmetry (less than 10 cc/sec); recurrent urinary tract infections secondary to obstruction; or stricture disease requiring periodic dilatation every 2 to 3 months
- 30%: Urinary retention requiring intermittent or continuous catheterization
Urinary tract infection and chronic prostatitis
This is the rating category for veterans with documented recurrent prostatic or urinary tract infections. The ladder runs as follows.
- 0%: Recurrent symptomatic infection not requiring hospitalization, but requiring suppressive drug therapy for less than 6 months
- 10%: Recurrent symptomatic infection requiring 1 to 2 hospitalizations per year or suppressive drug therapy lasting six months or longer
- 30%: Recurrent symptomatic infection requiring drainage by stent or nephrostomy tube; or requiring greater than 2 hospitalizations per year; or requiring continuous intensive management
When infection causes poor renal function, § 4.115a says to rate it as renal dysfunction instead, on the kidney function scale explained in the kidney disease guide.
Chronic prostatitis is rated here, because DC 7525 says to rate it as urinary tract infection. This is also the rating basis for BPH when recurrent infections documented in the medical record, rather than voiding symptoms, are the main problem.
Is BPH presumptive for Agent Orange or the PACT Act?
No. The Agent Orange list in 38 CFR § 3.309(e) includes prostate cancer, not BPH or chronic prostatitis. The PACT Act list in 38 USC § 1120 covers reproductive cancer of any type, which reaches prostate cancer, but it does not list BPH or prostatitis. The Camp Lejeune list in § 3.309(f) does not list them either.
That does not mean presumptions never come up. In my Board data, more than half of the service connection rulings on non-cancer prostate conditions raised a presumption, and those claims were granted at about the same rate as direct claims; the Board section below shows the claim theory breakdown. The data does not split that group by exposure framework, so I can't say how many involved herbicide, burn pit, Camp Lejeune, radiation or Gulf War theories. Three patterns explain how a presumption can matter for a non-cancer prostate claim.
Pattern A: Cancer history with non-cancer post-treatment residuals. The veteran was previously diagnosed with service-connected prostate cancer (Agent Orange or PACT Act presumptive), completed treatment, and now has chronic urinary symptoms. Those symptoms are rated as residuals of the cancer under DC 7528, as voiding or renal dysfunction, rather than as a separate BPH claim.
Pattern B: Camp Lejeune water exposure for non-cancer prostate conditions. The Camp Lejeune presumptive list for compensation, 38 CFR § 3.309(f) (with the service rule in § 3.307(a)(7)), covers bladder cancer and kidney cancer among its eight diseases but doesn't list BPH or prostatitis. Veterans can claim under § 3.310 secondary service connection, arguing the prostate condition was caused or aggravated by a condition service connected under the Camp Lejeune presumption. That needs a medical opinion explaining the link.
Pattern C: Herbicide exposure on a direct theory. Some veterans claim BPH or chronic prostatitis as related to herbicide exposure under direct (non-presumptive) service connection, citing the same scientific framework that supports the cancer presumption. The prostate cancer presumption does not carry over to BPH, so this needs a medical opinion that explains why the exposure, rather than age, caused the condition.
The data does not break the presumptive rulings down by pattern, so it cannot say which of these drove the results. To check which presumptions your service supports, use the presumptive conditions tool.
BPH and urinary problems after prostate cancer treatment
Veterans previously diagnosed and treated for service-connected prostate cancer often develop chronic urinary symptoms post-treatment. Surgical residuals from radical prostatectomy can include voiding dysfunction, erectile dysfunction, and a narrowing where the bladder joins the urethra (an anastomotic stricture). Radiation residuals can include radiation cystitis and radiation proctitis.
When these residuals develop, the rating analysis stays within the genitourinary chapter. The cancer rating itself drops from 100 percent to the residuals-based level after the mandatory examination six months after treatment (under DC 7528), which rates residuals as voiding dysfunction or renal dysfunction, whichever is predominant. Urinary problems caused by the cancer or its treatment are rated as those residuals rather than as a separate BPH claim, and 38 CFR § 4.14 bars rating the same symptom twice.
For veterans whose cancer was service-connected presumptively, this cascade is structurally favorable. The presumption did the connection work once. Subsequent residuals don't need additional service-connection development.
BPH that started before service: the aggravation question
Some veterans entered service with mild prostate symptoms that aren't formally documented at entrance. They develop more significant BPH or chronic prostatitis during service. The question becomes whether the condition existed before service and, if so, whether service aggravated it.
When a condition isn't noted at entrance, the veteran is presumed to have been in sound condition under 38 USC § 1111 and 38 CFR § 3.304(b). VA can rebut that presumption only with clear and unmistakable evidence that the condition existed before service and was not aggravated by it. When a condition is noted at entrance, 38 CFR § 3.306 applies: it is presumed to have been aggravated by service if there was an increase in disability during service, unless the increase was due to the natural progress of the disease.
For BPH specifically, the natural-progression question is medically complicated. BPH becomes steadily more common with age regardless of military service. Distinguishing "aggravated by service" from "naturally progressed during service" takes a medical opinion that addresses the condition's natural course.
My current Board data does not split out aggravation claims, so I can't give you a grant rate for this path. The aggravation framework is technically available, but the natural-progression question makes it a hard path for BPH.
How to prove BPH is service connected
The evidence that carries these claims falls into a few groups.
Documented in-service symptoms or treatment. Service treatment records showing urinary symptoms, BPH diagnosis, or chronic prostatitis treatment during active duty establish the direct service connection foundation. Veterans who entered service asymptomatic and developed documented BPH or chronic prostatitis during service have a clean path under direct service connection.
Continuity of treatment post-service. Medical records showing ongoing urological treatment, BPH medications (alpha-blockers, 5-alpha reductase inhibitors), or chronic prostatitis management establish the condition's chronicity and ongoing severity.
Symptom-specific documentation. The rating analysis depends on which symptom is predominant. Voiding dysfunction needs documentation of incontinence and absorbent material use. Urinary frequency needs voiding interval documentation. Urinary tract infection needs treatment records for recurrent infections. Obstructed voiding needs catheterization records or measured findings such as post void residuals or peak flow rate. The C&P examination and the treating urologist's records need to engage with the specific symptom category that supports the rating tier sought. A voiding log kept in the symptom tracker, with daytime intervals, nighttime awakenings and pad changes, maps directly onto the criteria.
Secondary theory through prostate cancer. For veterans with previously service-connected prostate cancer, claiming subsequent non-cancer prostate symptoms as residuals or as separately service-connected secondary conditions is often the structurally cleaner path than trying to establish independent service connection.
Camp Lejeune adjacency claims. Veterans with qualifying Camp Lejeune service may be able to claim prostate conditions as secondary to a condition service connected under the Camp Lejeune presumption, such as bladder cancer, but only where the medical record documents a downstream relationship.
Why VA denies BPH claims
Non-cancer prostate claims do a little worse at the Board than the average claim. Across 5,302 decided Board rulings on prostate conditions other than cancer from 2021 to 2026, 22.7% were granted, 32.8% denied and 44.5% remanded. That grant rate is 2.0 points below the Board-wide 24.7 percent.
When the Board denied service connection for these conditions, it most often found no link to service, and less often no qualifying in-service event; a missing current diagnosis came up least. The patterns behind those findings repeat.
Age as the explanation. BPH becomes common with age, and an examiner who sees no urinary complaints in service attributes the enlarged prostate to aging, not service.
No in-service symptoms. Service treatment records are silent, and the first urology visit comes years after discharge with nothing in between.
A presumption that does not apply. The claim relies on the Agent Orange or PACT Act prostate cancer presumption for BPH or prostatitis, which those lists do not cover, and no direct theory was developed.
A secondary opinion that skips aggravation. For a prostate condition claimed secondary to another service-connected condition, the opinion has to answer two questions: whether that condition caused it, and whether it was aggravated by the veteran's service-connected condition, meaning it would be less severe but for that condition. An opinion that says only "not caused by" and never addresses aggravation is inadequate.
Records that do not match the criteria. For rating appeals, the record has no voiding intervals, nighttime counts, pad changes, catheter use or infection treatment, so the next level is unproven.
When the Board sends one of these claims back instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get and claims that never had a VA exam. The Board section below shows how often each denial and remand reason came up and what happened after a remand.
Questions veterans ask about BPH
Is BPH a VA disability?
Yes, if it is service connected. VA rates BPH, an enlarged prostate, under DC 7527 through its urinary symptoms. Because BPH becomes common with age, the claim needs evidence that it began in or was caused by service, such as urinary complaints in service treatment records and a medical opinion.
What is the VA rating for an enlarged prostate?
VA rates an enlarged prostate as voiding dysfunction or urinary tract infection, whichever is predominant. Urinary frequency is rated 10, 20 or 40 percent, obstructed voiding 0, 10 or 30 percent, urine leakage 20, 40 or 60 percent, and recurrent infection 0, 10 or 30 percent.
What is the highest VA rating for BPH?
Usually 60 percent, for urine leakage that requires an appliance or absorbent pads changed more than four times a day. If infections have damaged kidney function, VA rates them as renal dysfunction instead, which can go higher.
Does VA rate waking up at night to urinate?
Yes. Under the urinary frequency criteria, waking to urinate two times a night is 10 percent, three to four times is 20 percent, and five or more times is 40 percent. Short daytime voiding intervals can meet the same levels.
Is BPH presumptive for Agent Orange or burn pits?
No. The Agent Orange list includes prostate cancer but not BPH, and the PACT Act list covers reproductive cancers, not benign prostate enlargement. BPH needs direct service connection, or a secondary claim if a service-connected condition caused or worsened it.
How does VA rate chronic prostatitis?
Chronic prostatitis is listed under DC 7525, which says to rate it as urinary tract infection. That means 0, 10 or 30 percent depending on hospitalizations, suppressive drug therapy, drainage or intensive management.
Bottom Line
Non-cancer prostate conditions rate under 38 CFR § 4.115b DC 7527 (or DC 7525 for chronic prostatitis), which routes the rating to whichever genitourinary symptom category is predominant: voiding dysfunction (urine leakage, urinary frequency, or obstructed voiding) or urinary tract infection. Across 5,302 decided Board rulings on prostate conditions other than cancer from 2021 to 2026, 22.7 percent were granted, 9.6 points below prostate cancer, and remand was the most common outcome. Claims argued under a presumption did about as well as direct claims, likely because the presumptions reach these conditions only through a service-connected prostate cancer. In rating appeals, the tier criteria are the whole question, particularly for urine leakage, where the number of pad changes per day decides the level. Among rulings the Board granted or denied, a private medical opinion in the record went with a higher grant rate, an association rather than a cause. For veterans with service-connected prostate cancer history, claiming subsequent prostate conditions as residuals or secondary is structurally favorable. For veterans without that foundation, the direct lane requires clean in-service documentation and engagement with the specific symptom-category criteria in 38 CFR § 4.115a.
Methodology and Limitations
- Data source: 38 CFR § 4.115b DC 7527 (prostate gland injuries, infections, hypertrophy, postoperative residuals, bladder outlet obstruction), DC 7525 (chronic prostatitis) and DC 7528 (genitourinary cancers), 38 CFR § 4.115a (genitourinary dysfunction rating criteria), 38 CFR § 4.14 (rating the same disability twice), 38 CFR § 3.310 (secondary service connection), 38 USC § 1111 and 38 CFR §§ 3.304(b) and 3.306 for pre-existing conditions, 38 USC § 1116 and 38 CFR § 3.309(e) (Agent Orange), 38 USC § 1120 (PACT Act), 38 CFR §§ 3.307(a)(7) and 3.309(f) (Camp Lejeune), and Claim Raven's read of 511,036 Board decisions from 2021 to 2026, which contain 1,378,030 rulings, including 5,749 rulings on prostate conditions other than cancer. Medical sources, read as PubMed abstracts: Ng and colleagues, "Benign Prostatic Hyperplasia," StatPearls (2024), for BPH prevalence by age and its urinary effects; Irwin, "Common Male Genitourinary Issues," FP Essentials (2026), for alpha-blockers and 5-alpha reductase inhibitors; Unger and colleagues, JAMA Oncology (2024), for urinary and sexual complications after prostatectomy and radiation cystitis and proctitis after radiotherapy; and Giúdice and colleagues, International Brazilian Journal of Urology (2019), for anastomotic stricture after radical prostatectomy.
- Sample size: Across 5,302 decided Board rulings on prostate conditions other than cancer from 2021 to 2026, 22.7% were granted (1,204), 32.8% denied (1,739) and 44.5% remanded (2,359). Dismissed, withdrawn and moot rulings are excluded. Breakdowns by claim theory, appeal type, medical opinion and denial and remand reasons appear in the Board section below, computed from the same data. Medical opinion findings record what the Board credited, not grades of evidence quality, and evidence figures are associations, not causes. The prostate cancer comparison uses that condition's own 7,485 decided rulings.
- Limitations: The data captures Board-level rulings and isn't representative of all non-cancer prostate claims filed with VA. The distinction between cancer and non-cancer prostate conditions follows how each ruling names the condition; some rulings involve both diagnoses with the rating analysis crossing between DC 7527 and DC 7528. The data does not record which rating tier a grant landed on or split out aggravation claims. The Camp Lejeune presumptive framework continues to be litigated and expanded, and current regulatory text controls over older interpretations. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.